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Introduction: Patients with transient ischemic attack (TIA) andminor stroke demonstrate
cognitive impairment, and a four-fold risk of late-life dementia.
Aim: To study the extent to which the rates of brain volume loss in TIA patients differ
from healthy controls and how they are correlated with cognitive impairment.
Methods: TIA or minor stroke patients were tested with a neuropsychological battery
and underwent T1 weighted volumetric magnetic resonance imaging scans at fixed
intervals over a 3 years period. Linear mixed effects regression models were used to
compare brain atrophy rates between groups, and to determine the relationship between
atrophy rates and cognitive function in TIA and minor stroke patients.
Results: Whole brain atrophy rates were calculated for the TIA and minor stroke
patients; n = 38 between 24 h and 18 months, and n = 68 participants between 18
and 36 months, and were compared to healthy controls. TIA and minor stroke patients
demonstrated a significantly higher whole brain atrophy rate than healthy controls over a
3 years interval (p= 0.043). Diabetes (p= 0.012) independently predicted higher atrophy
rate across groups. There was a relationship between higher rates of brain atrophy and
processing speed (composite P = 0.047 and digit symbol coding P = 0.02), but there
was no relationship with brain atrophy rates and memory or executive composite scores
or individual cognitive tests for language (Boston naming, memory recall, verbal fluency
or Trails A or B score).
Conclusion: TIA andminor stroke patients experience a significantly higher rate of whole
brain atrophy. In this cohort of TIA and minor stroke patients changes in brain volume
over time precede cognitive decline.
Keywords: brain, transient ischemic attack, stroke, cognition battery, atrophy rates, diffusion weighted imaging,
white matter lesion, longitudinal
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INTRODUCTION
Transient ischemic attack (TIA) and minor stroke, traditionally
considered as risk factors for major ischemic stroke, are common
medical emergency (incidence 0.37–1.1 per 1,000) associated
with a four-fold increase risk of cognitive decline and dementia
(1–3). Mechanisms linking TIA and minor stroke with cognitive
decline are poorly understood. More than a third of patients
with TIA have impairment of more than one cognitive domain
within 3 months of their TIA that is not entirely explained by
silent brain infarcts (4). Pathological studies link late life cognitive
impairment and brain atrophy to two dominant disease entities,
Alzheimer’s disease (AD) and small vessel disease (5, 6). Fifty
per cent of late-life cognitive impairment is attributed to vascular
and lifestyle-related risk factors in midlife. Still unknown are the
incipient disease processes which may contribute to cognitive
dysfunction, and whether these can be modified through vascular
risk reduction strategies guided by biologically relevant markers
of disease progression (7). For instance, early macroscopic brain
loss (i.e., volume loss in ml/year), measured by serial magnetic
resonance imaging (MRI), has been shown to be a predictor
of cognitive decline in AD and mild cognitive impairment (8).
Yet, studies identifying early incipient disease stroke and TIA
cohorts vary considerably in clinical selection criteria, cognitive
measures and methods for measuring changes in brain structure
over time (9–11).
In this longitudinal cohort study of non-demented TIA/minor
stroke patients, we hypothesize the TIA/minor stroke cohort
will have increased rates of cerebral brain atrophy (annualized
percent brain volume change, PBVC) compared to healthy
controls (HC) measured with repeated high-resolution
MR imaging. We aim to correlate PBVC with change in
neuropsychological performance over a 3 years period.
MATERIALS AND METHODS
Study Population
Patients were recruited from the Extended-CATCH (CT and
MRI in the Triage of TIA and minor Cerebrovascular events to
identify High risk patients) study (12) at the Foothills Medical
Center or Calgary Stroke Prevention Clinic from March 2009
to December 2012, while healthy controls were drawn from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. TIA
was diagnosed by disruptions to speech and motor symptoms
that lasted longer than 5min but <24 h. Minor ischemic stroke
was defined by a National Institute of Health Stroke Scale
(NIHSS) score of<4. Demographic andmedical information was
collected including vascular risk factors such as blood pressure,
body mass index (BMI), history of hypertension and diabetes.
Hypertension positive was defined as past medical history
of hypertension or is currently prescribed anti-hypertension
medications. MRI was acquired 48 h of symptoms (baseline),
at 18 months and 3 years. The MRI protocol at each time
point included a high-resolution T1-weighted and 3D FLAIR
sequences as described below.
Inclusion criteria for Ex CATCH TIA/minor stroke cohort
included: (1) age 50–80 years; (2) established vascular risk factors;
and (3) the acquisition of serial brain MRI scans at all 3 time
points. Exclusion criteria for Ex CATCH TIA/minor stroke
cohort included: (1) dementia as defined by the National Institute
of Aging-Alzheimer Association Criteria (13); (2) other central
nervous system diseases (e.g., MS), alcoholism, substance abuse,
sedatives, antipsychotic medications and history of psychiatric
illness that might impact cognitive testing and follow-up;
(3) Other comorbidities that could significantly interfere with
cognitive performance and functional outcome (e.g., recent
coronary bypass surgery, comorbidities), English as a second
language, and the inability to complete neuropsychological
testing. The University of Calgary Conjoint Health Research
Ethics Board formally approved the study, and all patients
provided written informed consent prior to participation.
The healthy control data used in the preparation of this article
were obtained from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was
launched in 2003 as a public-private partnership, led by Principal
Investigator Michael W. Weiner, MD. The primary goal of
ADNI has been to test whether serial MRI, positron emission
tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure
the progression of mild cognitive impairment (MCI) and
early Alzheimer’s disease (AD). For up-to-date information, see
www.adni-info.org. Well-characterized healthy control data was
obtained through ADNI, made permissible through approval by
the ADNI collaborators. The use of ADNI data for scientific
investigations has been established by other studies that compare
specific disease groups with the ADNI subjects (14–16).
ADNI inclusion criteria for healthy controls included a
Mini Mental State Examination (MMSE) score between 24
and 30, a Clinical Dementia Rating of 0, no indication of
depression, MCI, or dementia, cognitively normal, modified
Hachinski score ≤ 4, Geriatric Depression Scale <6, and normal
memory function. ADNI exclusion criteria included significant
neurological disease, MR evidence of infection, infarction, or
lesions, inability to complete MRI due to medical devices in
the body, psychiatric disorders, history of alcohol or substance
abuse, any significant illness or medical instability, use of
psychoactive medication.
Clinical Data Collection
At study entry baseline evaluation included clinical review,
fasting cholesterol, glucose, and renal function. Treatments for
hypertension, diabetes, hyperlipidemia, anti-thrombotic agents,
and other medications that could influence cognition such as
sedatives, anxiolytics, or psychotropic medications are collected.
We screened for obstructive sleep apnea (17). Blood pressure
(BP) measurement was recorded from average of 3 sitting BPs at
baseline and each subsequent visit. All participants are managed
according to current stroke prevention guidelines (18).
Image Acquisition
Extended CATCH TIA/Minor Stroke Cohort
To evaluate whole brain atrophy rates, TIA and minor stroke
patients underwent a T1-weighted volumetric acquisition using
a 3T scanner (Signa NV/I or Discovery 750; General Electric
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Healthcare, Waukesha, WI). High-resolution T1 images were
acquired at baseline (within 48 h of symptoms) and at follow-
up (TE/TR= 2.73 ms/7.0ms, flip angle = 8◦, TI = 650ms,
acquisition matrix = 256 × 256). 3D FLAIR (TE/TR/flip angle
140 ms/ 9,000 ms/90◦, acquisition matrix = 256 × 256) were
acquired at the same time points. Whole brain atrophy rates were
measured between baseline (within 48 h of stroke symptoms) and
18 months (Interval 1), and 18 months to 3 years (Interval 2).
In the middle of our study, a hardware upgrade occurred to a
GE Discovery 750 scanner preventing whole brain atrophy rates
being calculated at Interval 1 in those cases where MRI data
was acquired before the system upgrade. Quality assurance to
detect image distortion was conducted to assess the adequacy
of key image properties including image uniformity, image
contrast, and signal-to-noise. This visual imaging inspection was
performed on every scan and exclusion criteria and image quality
was graded according to neck and head movement, quality of
registration and intensity inhomogeneities.
For Extended CATCH subject a stroke neurologist and
neuroradiologist reviewed all images. Acute infarct location was
recorded as follows: (1) cortical (2) deep (basal ganglia, internal
capsule, thalamus, and deep white matter tracts) (3) cortical and
deep, and (4) infratentorial. DWI lesion volume were calculated
using Quantomo (Cybertrials Inc., Calgary, Canada), and have
been previously reported (19). For the segmentation of white
matter hyperintensities (WMHs) baseline and follow up fluid-
attenuated inversion recovery (FLAIR) images were registered
to the high-resolution T1 images using a rigid transformation
and cost function of the mutual information. WMH volume
(corrected for total intracranial volume) were calculated using
Cerebra-WML software, a semi-automated software measured
the volume (ml) of white matter lesions segmentation is based
on the global threshold and contrast between the different
anatomical regions of the brain (20), following international
recommendations for the reporting, image acquisition and
analysis of small vessel disease reported by our group (21, 22). To
evaluate the accuracy of these WM segmentations, two trained
clinicians conducted quality control of the semi- automated
segmentations by visually inspecting all the FLAIR images.
ADNI Healthy Controls
ADNI controls were imaged using the standardized ADNI
protocol (adni.loni.usc.edu/methods/documents/mri-protocols)
(23). Initial inspection of the ADN1-and ADNI GO database
revealed 417 healthy controls, and then identified 70 healthy
controls that met the age inclusion criteria, and had undergone
3T MRI at baseline, and follow up at years 1 and 3 years ± 6
months. 3T MRI data was download from the ADNI website
and included MRIs from Siemens Medical Solutions, Phillips,
and General Electric Healthcare. MR protocols included the
acquisition of sagittal high-resolution volumetric T1-weighted,
inversion recovery prepared, structural images, and 3D FLAIR.
MPRAGE (or vendor equivalent) high resolution T1 sequences
were acquired (TE = min full echo, TR + 2,300, TI = 900ms,
acquisition matrix = 256 × 256 @1 × 1 × 1mm) and SD
FLAIR (Effective TE = 119, TR = 4,800, T1 = 1,650, acquisition
matrix= 256× 256 @ 1.2× 1× 1mm).
Image Analysis
Measurement of Baseline Brain, Cortical Gray Matter,
and White Matter Volume
SIENAX (Structural Imaging Evaluation Using Normalization
of Atrophy, Cross-sectional) was used to measure the brain
volume, normalized for head size, cortical gray and white matter
volume (24, 25). Image analysis using SIENAX consists of 4
main steps: brain extraction, registration to MNI152 standard
template, standard-space masking, tissue-type segmentation, and
calculation of total brain volume.
Measurement of Whole Brain Atrophy Rates
Adetailed outline of the procedure is provided elsewhere (24, 25).
Measurement of whole brain atrophy rates was conducted using
SIENA (24). Each MRI underwent an imaging quality control,
which included ensuring proper brain extraction results that
did not include non-brain tissue, proper registration to MNI152
template and accurate segmentation of the whole-brain. Briefly,
the surface of the brain and the internal brain/cerebrospinal
fluid boundaries were identified automatically (Structural Image
Evaluation, using Normalization, of Atrophy, SIENA, part of
FMRIB Software Library, FSL; https://www.fmrib.ox.ac.uk/fsl),
followed by inspection and manual correction (26). These
corrections included distortion due to gradient non-linearity;
for image intensity non-uniformity (N3); for B1 non-uniformity
where required; and scaling based on ADNI phantom measures
(23). The 18 months and 3 years high resolution T1-weighted
acquisition were also registered to the baseline T1-w acquisition
via neighborhood-normalized cross-correlation.
Neuropsychological Assessment
TIA and minor stroke patients underwent neuropsychological
testing 90 days post ictus, and then annually for 3 years.
A modified version of the Canadian Stroke Network and
National Institute on Neurological Disorders and Stroke Vascular
Cognitive Impairment battery was used (27). The battery
tested frontal/executive, memory, language, and visuospatial
domains, and required ∼60–70min to administer. Specifically,
the tests used were: Trail making Test (Parts A and B) (28),
WAIS-III Digit Symbol Coding (29), Controlled Oral Word
Association Task (30), Boston Naming Test second edition—
short form (31), California Verbal Learning Test—II (32), Rey
Osterrieth Complex Figure Task (33), Boston Diagnostic Aphasia
Examination third edition—Complex Ideational Material subtest
(34), and CLOX1 clock drawing task (35). Domain-specific
composite z-score variables were created: (1) EF (average of Trails
B and COWAT FAS), (2) psychomotor processing speed, PS
(average of Trails B and Digit Symbol Coding), and (3) verbal
memory-Memory: CVLT List A Delayed Free Recall which was
calculated by taking the average of [2/3(average of trials 1–5)
+1/3(trials 12 and 12 false positives). Performance on composite
measures for each patient (19). Median (IQR) is reported in
the Table S1.
Statistical Analysis
Differences between TIA and minor stroke patients and ADNI
healthy controls demographic and clinical characteristics were
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tested using t-test or Fisher’s exact tests. An analysis of
variance was performed using all time points within each
neuropsychological test. A linear mixed effects regression model
with a random intercept was used to compare longitudinal
changes in brain atrophy between patients and healthy controls,
adjusting for demographic characteristics and vascular risk
factors. The linear mixed-effects regression model considers
the effects of both the within-subject and between-subject
variation. For example, a TIA/minor stroke patient can respond
differently over a longitudinal study with respect to brain volume
(within-subject) and the variation in response of each individual
patient may be different from another patient (between-subject).
In our study, we anticipated a linear relationship between
the independent and dependent variables. This relationship is
characterized by the linear coefficient, which highlights the trend
of the response variable with the predictor. Linear regression
helps model the outcome and response variables while still
incorporating patients who may vary in their independent
variable. The model is best suited to longitudinal studies as it can
incorporate missing values at specified time points of the study
design, such as missing imaging or neuropsychological.
Our analysis consisted of two parts: (1) to determine
whether Extended CATCH patients had increased whole brain
atrophy rates, a linear mixed-effects regression analysis was
employed to model atrophy rates between Extended-CATCH
with ADNI. The model incorporated independent covariates
that may independently modify whole brain atrophy rates
such as age (years), sex (female), time (years), and vascular
risk factors including history of hypertension, smoking, white-
matter hyperintensity volume (mL) and diabetes; (2) a series
of mixed effects regression models were estimated to determine
the relationship between baseline MRI (whole brain volume,
gray matter volume, white matter volume, and white matter
hyperintensity volume), and annualized percentage volume
change (PBVC) of whole brain with cognitive functioning defined
by the selected cognitive tests and for three cognitive domains
(executive function, processing speed and memory).
In the first part of the analysis, imaging time interval
was a dichotomous variable coded zero if the atrophy rate
measurement spanned 24 h to 18 months for patients or baseline
to 1 year for healthy controls (labeled as the first interval). It was
coded one if the atrophy rate measurement spanned 18 months
to 3 years for TIA/minor stroke patients or 1 year to 3 years for
ADNI data (labeled as the second interval). All atrophy rates were
annualized to account for differences in interval duration.
In the second part of the analysis, there was no comparative
neuropsychological data for the ADNI controls, in the TIA/
minor stroke cohort only, a series of linear mixed effects models
were used to estimate longitudinal cognitive test performance
vs. annualized rate of brain atrophy, while controlling for
demographic and medical characteristics, and including a
random slope and intercept for each participant. Covariates in the
cognitive outcome models are: Time of cognitive testing (years,
∼4 measurements beginning 90 days post-ictus and annually
for 3 years thereafter), age at first assessment (years), Education
(years), initial DiffusionWeighted Imaging Lesion Volume (mL),
baseline White Matter Hyperintensity Volume (mL), baseline
Gray Matter Volume, and baseline White matter volume. As
atrophy rate intervals (48 h, 18 months, 3 years) did not align
with cognitive testing (90 days, 1 year, 2 years, 3 years), they were
estimated as a time-varying covariate and grouped as follows:
interval 1 PBVC (48 h to 18 months) with first two cognitive
testing time points (90 days, 1 year); interval 2 PBVC (18 months
to 3 years) with second two cognitive testing time points (2 years,
3 years). To determine if the results were sensitive to grouping
of these variables, the 1 year and 2 years cognitive testing time
points were grouped with the opposite intervals in two models,
however no difference in results was noted.
In all mixed effects models described above, a subject-specific
intercept and slope was estimated for each participant. Mixed
effects regression permits modeling of longitudinal outcomes
using all available data, for example, if a participant is missing
the cognitive assessment at 2 years, a slope and intercept
for them would still be estimated based on their cognitive
performance at 90 days, 1 year, and 3 years while controlling
for atrophy rate and covariates. In a process analogous to meta-
analysis, these subject-specific regression lines are summarized
across participants while accounting for the added error due
to missing data points (36). Statistical analysis was carried
out using R (version 3.3.2, R Core Team) using the package
LME4 (36) and p < 0.05 was used to determine statistical
significance, except on the analysis of cognitive performance,
where a Bonferroni correction was applied to control for
inflation of the family-wise error rate producing a more
conservative significance threshold of p < 0.006. All mixed
effects models were fitted using Restricted Maximum Likelihood
estimation. Where appropriate means ± standard deviations
are reported.
RESULTS
Patient Demographics, Imaging and
Neuropsychological Outcomes
A total of 90 patients were recruited to the Extended-CATCH
study and those patients with 2 consecutive MRI scans by March
2014 were included into the study. Over the course of 3 years,
2 patients were deceased, 8 withdrew from the study, resulting
in 80 patients (10% attrition) completing the study at 3 years. A
total of 78 had baseline MRI, and cognitive assessment at least
two time points. Demographic data and vascular risk factors for
TIA and minor stroke patients, and healthy control participants
are summarized inTable 1. On average, the TIA andminor stroke
patient group were younger than the ADNI healthy control
group (p < 0.001), contained a higher proportion of men (p
< 0.001), those with hypertension (p = 0.005), and current
smokers (p = 0.002). The TIA and minor stroke patients had
significantly higher white matter hyperintensity volume (p <
0.001). Neuropsychological testing was performed for the patient
group on average 111 ± 24 days’ post-event, and then annually
for 3 years (year 1 = 430 ± 76 days; year 2 = 746 ± 43 days;
year 3 = 1,130 ± 43 days). In the Ex CATCH cohort there was a
significant improvement in compositememory andCVLT scores,
and digit symbol coding between baseline and 3 years (Table S1).
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TABLE 1 | Demographic and medical characteristics of TIA and minor stroke
patients and healthy controls.
Characteristics Patient group Healthy control
group
p
Number of subjects, n 80 70
Age, years 64.5 ± 12.7 70 ± 4.4 <0.001
Gender, males (%) 63 (78.8%) 32 (45.7%) <0.001
Hypertension, n (%) 42 (52.5%) 20 (28.6%) 0.005
Diabetes, n (%) 11 (13.8%) 3 (4.3%) 0.053
BMI, kg/m2 (SD) 27.2 ± 4.1 26.8 ± 6.8 0.685
Current Smoker, n (%) 10 (12.5%) 24 (34.3%) 0.002
White matter hyperintensity
volume, mL (SD)
10.2 ± 8.8 5.3 ± 6 <0.001
Annualized rate of atrophy
at first interval (SD)
−0.636 ± 0.552 −0.547 ± 0.813 0.503
Annualized rate of atrophy
at second interval (SD)
−0.966 ± 0.812 −0.583 ± 0.498 0.001
Normalized Brain volume,
mL (SD)
1400.4 ± 87.2 1,421 ± 79.1 0.551
Gray matter brain volume,
mL (SD)
724 ± 54.8 730.3 ± 46.3 0.847
White matter volume, mL
(SD)
675.5 ± 44.8 691.5 ± 45.5 0.316
Atrophy Rates
Whole Brain atrophy rates were calculated for 80 unique
participants: 39 participants over the first interval, and 72
participants over the second interval. One atrophymeasurements
over the first interval and 4 over the second-time interval were
excluded because one or both T1-weighted volumetric images
did not meet quality control criteria. Therefore, 38 subjects were
included in Interval 1 and 68 subjects in Interval 2. Twenty-eight
subjects had available MRI data from Interval 1 and 2. For the
ADNI group, 70 healthy controls were included in the study. A
total of 210 T1-weighted volumetric images were included: 70 at
baseline; 70 at 1 year; and 70 were available at 3 years.
Among patients over the first interval, a group mean whole
brain atrophy rate of−0.64± 0.55% was documented, compared
with −0.54 ± 0.32% for the healthy controls (p = 0.33). Over
the second interval, patients demonstrated a whole brain atrophy
rate of −0.97 ± 0.81% compared with healthy controls at −0.58
± 0.50% (p < 0.001). Overall, when pooled over both intervals,
in TIA/minor stroke patients the annualized whole-brain atrophy
rate was −0.85% ± 0.74 while in ADNI the annualized whole-
brain atrophy was−0.53%± 0.38 (p < 0.001).
Table 2 shows the association between annualized rate of
brain atrophy and group effect (TIA vs. controls) controlling
for subject demographic and vascular characteristics. TIA/minor
stroke patients demonstrated a higher annualized rate of brain
atrophy than ADNI controls. On average, patients with diabetes
demonstrated significantly higher levels of brain atrophy than
those without. But there was no evidence of any statistical
significant effect of imaging time interval, sex, hypertension,
BMI, smoking status or the baseline, WMH volume on
annualized rate of brain atrophy. As there appeared to be
TABLE 2 | Annualized whole brain atrophy rate of TIA and minor ischemic stroke
participants and healthy controls.
Unstandardized
regression
coefficient
95% CI p
Group (CATCH = 1,
ADNI = 0)
−0.228 [−0.462, −0.016] 0.043
Time (first interval = 0;
second interval = 1)
−0.155 [−0.324, 0.016] 0.09
Age (years) −0.01 [−0.021, 0] 0.051
Gender (female) −0.018 [−0.224, 0.147] 0.854
Diabetes −0.419 [−0.716, −0.085] 0.012
Hypertension 0.103 [−0.115, 0.292] 0.295
Current smoker 0.035 [−0.2, 0.253] 0.745
WMH Volume (mL) −0.013 [−0.025, −0.001] 0.057
WMH, white matter hyperintensity. The unstandardized regression coefficients (estimate)
are provided for each covariate.
no relationship with WMH volume and rates of whole brain
atrophy, additional statistical analysis of sub-classification of
WMH with brain atrophy or cognition was not performed.
The relationship between neuropsychological test
performance and atrophy rate is shown in Table 3. Each row in
Table 3 denotes a separate mixed-effects regression model where
the indicated cognitive outcome is estimated longitudinally
by atrophy rate and covariates. Only the regression weights,
confidence intervals, and p-values for atrophy rate are reported,
while the covariates are not. Table 3 shows that there is a modest
relationship with higher rates of brain atrophy and processing
speed composite and digit symbol coding but no relationship was
seen between brain atrophy rates andmemory, executive or other
individual cognitive test scores (CVLT, Boston Naming, Trails A
and B, verbal fluency). After correcting for multiple comparisons,
PBVC was not significantly associated with cognitive functioning
above and beyond the effects of time, age, DWI lesion volume,
education, white matter hyperintensity volume, baseline gray
matter volume, and baseline white matter volume. Neither was
there a relationship with baselineWMH volume, and normalized
brain volume (or gray and white matter volume) compared to
cognitive outcomes after applying Bonferroni correction to the
p-value. With regard to covariate significance after applying the
Bonferroni correction, the participants’ scores on the Memory
Composite Index [unstandardized regression weight = 0.19,
standard error = 0.03, t(40.73) = 6.17, p < 0.001] and the
California Verbal Learning Test [unstandardized regression
weight = 0.24, standard error = 0.036, t(36.85) = 6.71, p <
0.001] significantly improved over time. Education significantly
predicted Digit Symbol Coding total score above and beyond
the other variables [unstandardized regression weight = 0.09,
standard error= 0.03, t(71.17) = 2.91, p= 0.005].
DISCUSSION
This study shows that TIA andminor stroke patients experienced
higher whole-brain atrophy rates than healthy controls over a 3
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TABLE 3 | The relationship of annualized whole brain atrophy with neuropsychological test performance of Extended-CATCH patients.
Cognitive functioning composite/test
score
Unstandardized regression coefficient 95% CI Standardized regression coefficient p
Executive functioning composite (n = 78 with
195 observations)
0.103 [−0.096, 0.306] 0.076 0.328
Processing speed composite (n = 78 with 198
observations)
0.192 [0.006, 0.378] 0.139 0.045
Memory composite (n = 78 with 199
observations)
0.008 [−0.128, 0.148] 0.007 0.906
CVLT (n = 78 with 205 observations) −0.013 [−0.155, 0.144] −0.011 0.87
Boston short form (Total Score) (n = 78 with
201 observations)
−0.168 [−0.395, 0.053] −0.105 0.14
Trail making test—Part A (seconds) (n = 78
with 201 observations)
0.081 [−0.159, 0.32] 0.049 0.54
COWA (Total new words) (n = 78 with 200
observations)
−0.067 [−0.274, 0.136] −0.048 0.534
Trail making test—Part B (s) (n = 78 with 200
observations)
0.211 [−0.063, 0.488] 0.108 0.169
Digit-symbol coding (Total Score) (n = 78 with
200 observations)
0.199 [0.035, 0.366] 0.159 0.019
COWA, Controlled Oral Word Association Test (total score); CVLT, California Verbal Learning Test (Total recall = total recall over 5 learning trials; Delayed Recall = free recall after
20–25min); Each row denotes a separate mixed-effects regression model where the indicated cognitive outcome is estimated by atrophy rate and covariates. Only the regression
weights, confidence intervals, and p-values for atrophy rate are reported, while the covariates are not. Covariates are: Time of cognitive testing (years), Age (years), Lesion Volume
(mL), Education (years), White Matter Hyperintensity Volume (mL), Baseline Gray Matter Volume, Baseline White matter volume. Each Regression model is fit with a random slope and
intercept over time for each participant; Bonferroni-adjusted significance level set to p < 0.006.
The unstandardized regression coefficients (estimate) are provided for each covariate.
years period. In addition, age and presence of diabetes were also
significant predictors of whole-brain atrophy rate. But we did not
find evidence of a significant effect for history of hypertension,
sex, BMI, smoking status, or imaging time interval, or DWI
lesion volume, or normalized brain volume on brain atrophy
rates. The cognitive profile revealed that subjects who had more
delayed processing speed composite scores (WAIS-III Digit-
Symbol Substitution) had higher rates of whole brain atrophy.
However, these results were not significant after correcting for
multiple comparisons. Memory composite and CVLT scores
improved over the course of the study, and we found that digital
symbol coding was strongly related to educational attainment.
These results concur with the previous study of TIA patients that
revealed high rates of cerebral atrophy over a year which was
associated with higher diastolic blood pressure and white matter
hyperintensities (9). Our findings provide further evidence that
structural changes in the brain, in this case change in whole
brain volume, may underlie a heightened risk of dementia
in a TIA/ minor stroke patient population (37) and occurs
before deterioration in cognitive tests can be measured. The
measurement of whole brain atrophy rate may help identify high-
risk patients for targeted intervention. This data expands on
previous findings by demonstrating that patients show elevated
whole-brain atrophy rates early in the disease progression, before
symptoms or signs of cognitive decline develop (38, 39).
The use of rate of brain atrophy may have some advantages
as a surrogate marker of preclinical disease progression (40,
41). Rates of brain atrophy have been shown to correlate
with cognitive decline and vascular disease and AD (42).
Measurement of brain atrophy rate is also more sensitive
at predicting cognitive decline and can be measured more
precisely than neuropsychological outcomes (43), which are
subject to several potential confounders (e.g., baseline cognitive
performance, problems with standardization procedures, co-
morbid disease and treatment factors, and learning effects).
The link between TIA and minor stroke and late life
cognitive decline is not known, but a recent study has
established that cardiovascular risk factors appear to influence
neurodegeneration independent of amyloid markers of AD (44).
The progression of cognitive decline has been reported in
patients with stroke. In a recent prospective cohort study,
longitudinal telephone cognitive testing in participants aged
45 years or older was conducted pre and post stroke over 6
years (45). Those that experienced stroke were older men with
more vascular risk factors, low socio-economic indicators and
worse health status, and lower pre-stroke cognition. While acute
stroke was associated with acute decline in global cognition in
new learning and verbal memory, intriguingly participants with
incident stroke later had statistically significant faster declines
in global cognition and executive function than in learning or
verbal memory when compared to pre-stroke. Another study of
stroke and TIA patients detected progressive decline in verbal
memory 3 years post stroke in patients without clinical or
radiological evidence of recurrent stroke (10). The same study
also showed that decline in composite neuropsychological scores
was associated with smaller hippocampi, and brain atrophy at
3 years (as a cross-sectional measure) (10). Important potential
modifiers of decline in verbal memory and brain atrophy, such
as stroke size or location, incipient cerebrovascular disease,
presence of in vivo AD pathology were not established (46–49).
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Another recent study selected patients with “TIA presentation”
and CT perfusion deficits, and remarkably demonstrated cross-
sectional changes in whole brain volume from baseline to 90
days later (11). The paper did not report DWI volume despite
reporting moderately large CT perfusion deficits, and changes
in cortical gray matter volumes and decline in the Montreal
Cognitive Assessment was reported after a short follow-p period
of 90 days. Our data adds to these studies by demonstrating
improvement in memory and executive composite test scores
and relatively modest changes in other cognitive tests using
a comprehensive battery despite showing absolute changes in
whole brain volume over time.
Expanding on these studies, The Predementia Neuroimaging
of Transient Ischemic Attack (PREVENT) prospective
longitudinal cohort study is targeting patients presenting
with clinically defined motor or language TIA (50). These
subjects are generally younger, not demented and in better
physical condition than stroke patients, thereby permitting the
acquisition of detailed serial neuropsychological assessments in
participants that are not disabled and cooperative with cognitive
testing, and avoiding high attrition rates caused by stroke related
co-morbidity and frailty that can prohibit the study of cognition
over time (10). Prospective longitudinal studies design in
patients with cerebrovascular presentations utilizing serial high
resolution structural MRI and cognitive testing will permit more
precise estimates of the relationship of neurodegenerative disease
and progressive white matter lesions with rates of cerebral
atrophy and cognitive decline than cross-sectional studies.
Identifying the disease that contributes to the change in brain
volume will be important because the response to preventative
treatments may depend on the stage of disease and its pathology.
Currently available biomarkers include cerebrospinal fluid AD
biomarkers of tau and Aβ1−42 that precede cognitive decline and
correlate with atrophy (51, 52). Whole brain atrophy is a global,
non-specific indicator/marker of diffuse neurodegenerative
processes involved in disease such as AD but does not highlight
the regional changes that are known to exist through different
stages of disease progression in AD patients and cerebrovascular
disease (42).
The use of ADNI controls is a potential source of error,
however there is precedence for their use in similar comparison
studies (53, 54). We were careful to perform regular quantitative
and qualitative assessments to optimize signal to noise and
reduce image distortion related to uniform and geometric
fidelity according to manufacturer specifications. It has been
previously demonstrated that scanner variability related to field
strength (53, 54) and vendor (55) appears to have minimal
effect on such volumetric measurements. There was significant
disparity of age and gender between Extended CATCH and
HC groups. The ADNI subjects were on average 5 years older
than the TIA/ minor stroke group, yet despite being slightly
older, they had lower rates of cerebral atrophy across the two-
interval time points than the TIA and minor stroke group.
Additionally, the measurements of percentage annualized change
in brain volume that we have measured in our control subjects
conforms with published data (8, 26). The higher proportion
of men in the CATCH cohort is expected because men have a
higher incidence of TIA and stroke. Nevertheless, gender in our
analysis was not a predictor of increased rates of whole brain
atrophy. Another potential limitation is the under-diagnosis of
hypertension because we restricted our analysis to prior history of
hypertension or concurrent antihypertensive treatment. Finally,
our study population was compromised by the absence of whole
brain atrophy rate measurements in a substantial portion at
interval one because of technical reasons related to a MRI
system upgrade.
Our findings indicate that patients presenting with TIA and
minor stroke demonstrate greater brain atrophy rates than
healthy controls over a 3 years post-event period. The elevated
atrophy rate in this population was significant beyond the effects
of demographic and vascular risk factors. Whole brain atrophy
rates in TIA and minor stroke patients appear to be weakly
related to cognitive function. However, if neurodegenerative
changes continue and precede cognitive symptoms, atrophy rates
could be used to assess the efficacy of vascular risk factor-
reduction treatments. This would provide a therapeutic window
for slowing changes in brain volume that precede cognitive
decline in patients at a high risk of dementia.
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